Message #4 From:
NewsBot Date: August 17, 2006 06:06:00 AM
AMAR News Management Team of Amarillo Biosciences, Inc., Discuss Upcoming Studies and Successful Passing of FDA's 30-day Review Process for Company's Investigational New Drug Application for Idiopathic Pulmonary Fibrosis at SmallCapVoice.com
AUSTIN, Texas--(BUSINESS WIRE)--Aug. 17, 2006--SmallCapVoice.com, Inc. today announced that a new audio interview is available at SmallCapVoice.com. The featured guests are Joseph and Marty Cummins of Amarillo Biosciences (OTCBB:AMAR). The interview focuses on the recent news that the Company's Investigational New Drug application (IND) for idiopathic pulmonary fibrosis (IPF) has successfully passed the FDA's 30-day review process and has been allowed to go into effect. The interview can be heard here at http://www.smallcapvoice.com/amar/amar-8-16-06.html.
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 14% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.
